Some try risky sources for weight-loss drugs; Verily leans into Onduo as it embarks on running medical research

Websites are selling powders purporting to be the ingredients of popular new weight-loss drugs that have been hard to find. Clinicians are worried. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     Mix-it-yourself Wegovy? Some are trying risky sources for weight-loss drugs By Elaine Chen Christine Kao/STAT Websites are selling powders purporting to be the ingredients of popular new weight-loss drugs. Clinicians are worried. Read More STAT+: Verily leans into Onduo as it looks to enter the lucrative world of running medical research By Matthew Herper and Casey Ross Christine Kao/STAT After laying off staff, Verily plans to lean on its spinout Onduo as it looks to build a door into the lucrative world of running research. Read More HIV vaccine being developed by Johnson & Johnson fails clinical trial By Helen Branswell NIAID The trial was halted after a scheduled data review by the data and safety monitoring committee concluded that the HIV vaccine wasn't working. Read More Sponsored Insight by Organon This is the decade of biosimilar market growth As inflation continues to climb, it's more critical than ever to help reduce costs on the health care system and increase competition in biologic medicines. With so many biologic medications expected to come off patent, additional biosimilar medications may be developed. This new era of biosimilar competition may improve medication access. Read more about a future with biosimilars. STAT+: Hip and knee replacements go better when performed by high-volume surgeons, new study finds By Tara Bannow Adobe A new study finds better outcomes and lower costs when hip and knee replacements are performed by high-volume surgeons. Read More Opinion: Leaders at Davos need to pay attention to the crossroads of climate change, health, and security By Vanessa Kerry Reed Joshua/AP Climate change will be on the agenda at this year's World Economic Forum in Davos, but there's a piece of the climate puzzle missing: health. Read More In the search for therapies for solid tumors, companies are turning to a novel target: claudin-6 By Angus Chen Molly Ferguson for STAT Several biotech and pharma companies have begun developing bispecific antibodies or CAR-T cell therapies targeting claudin-6. Read More Opinion: Biopharma leaders helped save democracy. Now what? By Paul Hastings Adobe Leaders of biopharma and other companies helped nudge the Congress to pass the bipartisan Electoral Reform Act. Read More Wednesday, January 18, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser